Cardiff Oncology, Inc.

NasdaqCM:CRDF Rapport sur les actions

Capitalisation boursière : US$125.3m

Cardiff Oncology Gestion

Gestion contrôle des critères 3/4

Le PDG Cardiff Oncology est Mark Erlander, nommé en May2020, a un mandat de 4.5 ans. La rémunération annuelle totale est $ 1.55M, composée du salaire de 38.4% et des bonus 61.6%, y compris les actions et options de la société. détient directement 0.048% des actions de la société, d'une valeur de $ 59.98K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.8 ans et 10.2 ans.

Informations clés

Mark Erlander

Directeur général

US$1.5m

Rémunération totale

Pourcentage du salaire du PDG38.4%
Durée du mandat du directeur général4.5yrs
Propriété du PDG0.05%
Durée moyenne d'occupation des postes de direction2.8yrs
Durée moyenne du mandat des membres du conseil d'administration10.2yrs

Mises à jour récentes de la gestion

Recent updates

Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next

Nov 07

We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Oct 09
We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Oct 04

We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

Jun 19
We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 09

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Mar 03
We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Nov 16
Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 01
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Feb 22
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment

Sep 14

Cardiff Oncology: Down But Not Out

Aug 22

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Jun 20
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Upcoming Readouts And Several Green Lights

Jun 07

Cardiff Oncology: Risky Investment

May 19

Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

Mar 01

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Jan 28
We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Cardiff: The Pfizer Interest Is Interesting

Dec 15

Circling Back On Cardiff Oncology

Oct 12

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Current Slump Doesn't Look Right

Jun 14

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Apr 29
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

Feb 28
How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?

Jan 24
What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?

Analyse de la rémunération des PDG

Comment la rémunération de Mark Erlander a-t-elle évolué par rapport aux bénéfices de Cardiff Oncology?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

-US$43m

Jun 30 2024n/an/a

-US$41m

Mar 31 2024n/an/a

-US$40m

Dec 31 2023US$2mUS$594k

-US$41m

Sep 30 2023n/an/a

-US$41m

Jun 30 2023n/an/a

-US$40m

Mar 31 2023n/an/a

-US$39m

Dec 31 2022US$2mUS$571k

-US$39m

Sep 30 2022n/an/a

-US$39m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$4mUS$533k

-US$28m

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$23m

Mar 31 2021n/an/a

-US$24m

Dec 31 2020US$1mUS$445k

-US$23m

Sep 30 2020n/an/a

-US$20m

Jun 30 2020n/an/a

-US$20m

Mar 31 2020n/an/a

-US$17m

Dec 31 2019US$853kUS$399k

-US$17m

Sep 30 2019n/an/a

-US$17m

Jun 30 2019n/an/a

-US$16m

Mar 31 2019n/an/a

-US$19m

Dec 31 2018US$909kUS$387k

-US$19m

Sep 30 2018n/an/a

-US$18m

Jun 30 2018n/an/a

-US$18m

Mar 31 2018n/an/a

-US$20m

Dec 31 2017US$1mUS$374k

-US$25m

Rémunération vs marché: La rémunération totale de Mark ($USD 1.55M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 649.07K ).

Rémunération et revenus: La rémunération de Mark a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Mark Erlander (64 yo)

4.5yrs

Titularisation

US$1,547,772

Compensation

Dr. Mark Erlander, Ph D., is Chief Executive Officer of Cardiff Oncology, Inc. (formerly known as TrovaGene, Inc.) since May 2020 and was its Chief Scientific Officer March 4, 2013 to April 2020. Dr. Erlan...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Mark Erlander
CEO & Director4.5yrsUS$1.55m0.048%
$ 60.0k
James Levine
Chief Financial Officer3.3yrsUS$917.72k0.12%
$ 147.0k
Fairooz Kabbinavar
Chief Medical Officer1.8yrsUS$1.26m0%
$ 0
Tod Smeal
Chief Scientific Officer2.8yrsUS$4.17m0%
$ 0
Elizabeth Anderson
VP of Finance & Administration9.3yrspas de donnéespas de données
Brigitte Lindsay
Senior Vice President of Finance1.8yrspas de donnéespas de données
Charles Monahan
Senior Vice President of Regulatory Affairs2.8yrspas de donnéespas de données

2.8yrs

Durée moyenne de l'emploi

61.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de CRDF est considérée comme expérimentée (ancienneté moyenne 2.8 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Mark Erlander
CEO & Director4.4yrsUS$1.55m0.048%
$ 60.0k
Charles Cantor
Member of Scientific Advisory Boardno datapas de donnéespas de données
Gary Pace
Independent Director4.6yrsUS$114.43k1.36%
$ 1.7m
K. Hirth
Member of Scientific Advisory Board10.3yrspas de donnéespas de données
Paul Billings
Member of Scientific Advisory Board12yrsUS$35.85kpas de données
Rodney Markin
Independent Chairman of the Board10.8yrsUS$154.43k0.061%
$ 76.1k
Carlo Croce
Member of Scientific Advisory Boardno datapas de donnéespas de données
Riccardo Dalla-Favera
Member of Scientific Advisory Board14.6yrspas de donnéespas de données
Lale White
Independent Director4.6yrsUS$116.43k0.22%
$ 278.8k
Alberto Bardelli
Member of Scientific Advisory Board10.2yrspas de donnéespas de données
Renee Tannenbaum
Independent Director3.4yrsUS$110.43k0.020%
$ 24.5k
Brunangelo Falini
Member of Scientific Advisory Board14.6yrspas de donnéespas de données

10.2yrs

Durée moyenne de l'emploi

72yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la CRDF est chevronné et expérimenté ( 10.2 années d'ancienneté moyenne).